2010 Fiscal Year Final Research Report
Combination adjuvant therapy using chemotherapy and immunotherapy for pancreatic cancer: assessment of safety and efficacy.
Project/Area Number |
20591623
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | The University of Tokyo |
Principal Investigator |
AOKI Taku The University of Tokyo, 医学部附属病院, 講師 (30302722)
|
Co-Investigator(Kenkyū-buntansha) |
HASEGAWA Kiyoshi 東京大学, 医学部附属病院, 准教授 (20292906)
KOKUDO Norihiro 東京大学, 医学部附属病院, 教授 (00205361)
KAKIMI Kazuhiro 東京大学, 医学部附属病院, 特任准教授 (80273358)
|
Project Period (FY) |
2008 – 2010
|
Keywords | 膵臓外科学 / 化学療法 / 免疫療法 |
Research Abstract |
An adjuvant therapy using combination of Gemcitabine and auto γδ T lymphocyte immunotherapy was conducted for postoperative patients with pancreatic cancer. Twenty-two patients were enrolled and actually 11 patients received the combination therapy. The safety of the therapy was confirmed, but the benefit for disease-free survival was unclear. Further follow-up will be needed.
|
-
-
-
-
-
[Journal Article] Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.2008
Author(s)
Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K
-
Journal Title
Cytotherapy 10(8)
Pages: 842-856
Peer Reviewed
-
-
-
-
-
[Remarks] ホームページ等